{"id":97971,"date":"2009-12-23T12:00:31","date_gmt":"2009-12-23T17:00:31","guid":{"rendered":"http:\/\/blogs.wsj.com\/health\/2009\/12\/23\/deals-from-pfizer-novartis-and-astrazeneca-also-snake-oil\/"},"modified":"2009-12-23T12:00:31","modified_gmt":"2009-12-23T17:00:31","slug":"deals-from-pfizer-novartis-and-astrazeneca-also-snake-oil","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/97971","title":{"rendered":"Deals from Pfizer, Novartis and AstraZeneca. Also: Snake Oil."},"content":{"rendered":"<p><img decoding=\"async\" src=\"http:\/\/s.wsj.net\/media\/placebo_art_257_20080304155738.jpg\" alt=\"Drug\" align=\"right\"\/>A few quick drug-industry items:<\/p>\n<p><strong>Novartis is <a href=\"http:\/\/www.corthera.com\/investor20091222.html\" >buying<\/a><\/strong> closely held Corthera for $120 million. That gives the company the rights to a drug called Relaxin, which is in late-stage trials for acute heart failure. Current Corthera shareholders could get hundreds of millions more in milestone payments if the drug pans out (always an iffy proposition). <\/p>\n<p>Novartis is also likely to expand its stake in Alcon soon, <a href=\"http:\/\/blogs.wsj.com\/deals\/2009\/12\/22\/look-for-novartis-alcon-deal-in-early-2010\/\" >WSJ&#8217;s Deal Journal<\/a> said yesterday. The company <a href=\"http:\/\/blogs.wsj.com\/health\/2008\/04\/07\/novartis-spends-big-on-diversification\/\" >already has purchased<\/a> a quarter of the company from Nestl\u00e9 and is likely to buy another 52%, maybe more. Alcon sells eye-care products, and the buy is a diversification play.<\/p>\n<p><strong>AstraZeneca will pay $350 million to buy Novexel<\/strong>, a company that specializes in new antibiotics, plus another $80 million for the company&#8217;s cash. Forest Labs is also in on the deal &#8212; the company will pay AstraZeneca half of what it spent on the Novexel deal, and will share development costs of Novexel&#8217;s lead experimental compounds. The medicines aim to treat infections that are resistant to existing antibiotics. For all of the wrinkles in the deal, see this story from <a href=\"http:\/\/online.wsj.com\/article\/BT-CO-20091223-707023.html\" >Dow Jones Newswires<\/a>.<\/p>\n<p><strong>Pfizer is licensing an experimental drug out<\/strong> to Medicines Co., a small drug maker. Despite the deal&#8217;s size, (the upfront payment is only $10 million), it&#8217;s a good reminder that deals can flow both ways: Besides prowling for drugs to bring in from smaller players, giants like Pfizer also have drugs in their pipeline they&#8217;re looking to license out for a price. In this case, the drug is a cholesterol medicine called ApoA-I Milano, described in <a href=\"http:\/\/jama.ama-assn.org\/cgi\/content\/abstract\/290\/17\/2292\" >this clinical trial<\/a> published in JAMA in 2003.<\/p>\n<p><strong>Amgen and Roche ended a long fight<\/strong> over anemia drugs. Roche admitted that certain Amgen patents are valid, enforceable and infringed on by Roche&#8217;s anemia drug Mircera, <a href=\"http:\/\/online.wsj.com\/article\/SB10001424052748703478704574612912946326796.html\" >Reuters reports<\/a>. That means Amgen&#8217;s drug Aranesp isn&#8217;t likely to face generic competition in the U.S. until 2014. A court had already <a href=\"http:\/\/blogs.wsj.com\/health\/2008\/10\/03\/in-us-amgen-wont-face-competition-from-roche\/\" >issued an injunction<\/a> keeping Mircera off the market here.<\/p>\n<p>Earlier filings in the case were pretty spirited. \u0093With all the sincerity of a snake-oil salesman, Roche hyped its infringing product as a purportedly \u0091new\u0092 medicine conferring a different medical benefit,\u0094 Amgen&#8217;s lawyers <a href=\"http:\/\/blogs.wsj.com\/health\/2008\/02\/19\/amgen-compares-roche-to-snake-oil-salesman\/\" >wrote<\/a>. Roche said it had acted fairly.<\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~at\/aUr_7gC4ov1LLbeOUbkyZpimflU\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~at\/aUr_7gC4ov1LLbeOUbkyZpimflU\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~at\/aUr_7gC4ov1LLbeOUbkyZpimflU\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~at\/aUr_7gC4ov1LLbeOUbkyZpimflU\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<div class=\"feedflare\">\n<a href=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?a=bwDY6FkYcGk:ZRO7X5QQ498:yIl2AUoC8zA\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?d=yIl2AUoC8zA\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?a=bwDY6FkYcGk:ZRO7X5QQ498:D7DqB2pKExk\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?i=bwDY6FkYcGk:ZRO7X5QQ498:D7DqB2pKExk\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?a=bwDY6FkYcGk:ZRO7X5QQ498:F7zBnMyn0Lo\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?i=bwDY6FkYcGk:ZRO7X5QQ498:F7zBnMyn0Lo\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?a=bwDY6FkYcGk:ZRO7X5QQ498:V_sGLiPBpWU\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?i=bwDY6FkYcGk:ZRO7X5QQ498:V_sGLiPBpWU\" border=\"0\"><\/img><\/a> <a href=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?a=bwDY6FkYcGk:ZRO7X5QQ498:qj6IDK7rITs\"><img decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~ff\/wsj\/health\/feed?d=qj6IDK7rITs\" border=\"0\"><\/img><\/a>\n<\/div>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/wsj\/health\/feed\/~4\/bwDY6FkYcGk\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A few quick drug-industry items: Novartis is buying closely held Corthera for $120 million. That gives the company the rights to a drug called Relaxin, which is in late-stage trials for acute heart failure. Current Corthera shareholders could get hundreds of millions more in milestone payments if the drug pans out (always an iffy proposition). [&hellip;]<\/p>\n","protected":false},"author":650,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-97971","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/97971","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/650"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=97971"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/97971\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=97971"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=97971"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=97971"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}